Muscle Wasting Disorders Market Report 2026

The muscle wasting disorders market size has grown rapidly in recent years. It will grow from $17.49 billion in 2025 to $19.96 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to prevalence of muscular dystrophy and als, increased use of physical therapy, rise in nutritional supplement usage, early adoption of anti-inflammatory treatments, growth in hospital-based rehabilitation services.

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $33.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to advancements in gene therapy technologies, growing investment in regenerative medicine, expansion of specialized rehab centers, increasing demand for personalized treatment plans, rising focus on nutritional interventions. Major trends in the forecast period include rising adoption of gene therapy for muscle regeneration, growing use of nutritional and protein supplementation, increased demand for physical rehabilitation programs, expansion of targeted therapies for muscular dystrophy, rising utilization of hormonal and anti-inflammatory medications.

Rising adherence to a sedentary lifestyle is expected to drive the growth of the muscle wasting disorders market going forward. A sedentary lifestyle is characterized by minimal physical activity and limited engagement in regular exercise or movement. Prolonged sedentary behavior can adversely affect muscle function, leading to reduced muscle strength and endurance, contributing to the development of muscle wasting disorders, and making it more challenging for individuals to preserve muscle mass and functional capacity. For instance, in March 2025, according to NHS England, a UK-based executive non-departmental public body, more than one-quarter of adults were classified as inactive, while nearly one-third of children and young people (30.2%) in 2023 engaged in less than 30 minutes of physical activity per day. Therefore, increasing adoption of sedentary lifestyles is fueling the growth of the muscle wasting disorders market.

Major companies operating in the muscle wasting disorders market are focusing on developing innovative products, such as novel gene therapies, to better address the needs of patients with muscle wasting conditions. Novel gene therapy is a medical approach designed to achieve therapeutic benefits by modifying gene expression or altering the biological characteristics of living cells. For example, in June 2023, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys, the first gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 to 5 years. Elevidys is a recombinant gene therapy engineered to deliver a gene that produces a shortened form of the dystrophin protein, incorporating selected functional domains found in normal muscle cells. The therapy is administered as a single intravenous infusion.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. Through this acquisition, Biogen aims to strengthen its rare disease portfolio by adding Friedreich’s ataxia, a genetic, progressive, life-shortening, and debilitating condition that affects both the nervous system and muscles. Reata Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of therapies for neuromuscular and muscle wasting disorders.

Major companies operating in the muscle wasting disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Cytokinetics Incorporated, Scholar Rock, Akashi Therapeutics, aTyr Pharma, MyoTherix Inc., Pephexia Therapeutics, Biophytis SA, TNF Pharmaceuticals Inc., Rejuvenate Biomed, Edgewise Therapeutics.

North America was the largest region in the muscle wasting disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscle wasting disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical components, medical devices, and rehabilitation equipment have increased overall treatment costs in the muscle wasting disorders market, particularly affecting regions dependent on imported medications and assistive devices. Segments such as anabolic steroids, hormonal therapies, orthopedic surgical tools, and rehabilitation machinery experience higher procurement costs and delayed supplies. However, tariffs have driven local production initiatives and technological innovation, enabling long-term cost reductions and increased regional self-sufficiency.

The muscle wasting disorders market research report is one of a series of new reports that provides muscle wasting disorders market statistics, including muscle wasting disorders industry global market size, regional shares, competitors with a muscle wasting disorders market share, detailed muscle wasting disorders market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. This muscle wasting disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Muscle wasting disorders, also known as muscle atrophy or muscle wasting, refer to a group of conditions characterized by the progressive loss of muscle mass and strength. This can result from various factors, including disuse, aging, malnutrition, neurodegenerative diseases, and certain medical conditions.

The main treatments for muscle wasting disorders include medications, physical therapy, nutritional therapy, surgery, gene therapy, and others. Medications for muscle wasting disorders are used to treat conditions such as sarcopenia, cachexia, and muscular dystrophy and are intended to increase muscle mass and enhance muscle function. These treatments are applied for disorders including muscular dystrophy and amyotrophic lateral sclerosis (ALS) and are used by hospitals, rehabilitation centers, specialty clinics, and other end users.

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.